BNGO

BNGO

USD

Bionano Genomics Inc. Common Stock

$3.700+0.030 (0.817%)

リアルタイム価格

Healthcare
Medical Instruments & Supplies
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$3.670

高値

$3.780

安値

$3.660

出来高

0.05M

企業ファンダメンタルズ

時価総額

12.4M

業種

Medical Instruments & Supplies

United States

取引統計

平均出来高

0.14M

取引所

NCM

通貨

USD

52週レンジ

安値 $2.68現在値 $3.700高値 $52.2

関連ニュース

Analyst Upgrades

Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target

Maxim Group analyst Jason McCarthy upgrades Bionano Genomics from Hold to Buy and announces $8 price target.

もっと見る
Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target
GlobeNewswire

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full

もっと見る
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
GlobeNewswire

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report

もっと見る
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome

もっと見る
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers